Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
MPS I
Disease Information
Management of MPS I Disease
Medical Information Services
Pharmacovigilance & Safety Information
IgG AB testing service
MPS I Registry
Practical Info
Request Materials
Pompe

 



 

Pharmacovigilance / Safety Information

Genzyme maintains a worldwide database of adverse events that have occurred in patients receiving Aldurazyme® enzyme replacement therapy.

Please promptly report all adverse events (infusion-related or otherwise) by completing an Adverse Event Form and fax it to +32 2 714 17 07.

You can also call Genzyme Belgium at +32 2 714 17 11 or e-mail us.

In case of unexpected adverse events, a search for comparable events can be requested. The report on such a search may be helpful in the evaluation and management of unexpected events.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with Cerezyme®

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with Fabrazyme® significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease